Title: Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugates.
Authors: Shuvaev, Vladimir V; Muro, Silvia; Arguiri, Evguenia; Khoshnejad, Makan; Tliba, Samira; Christofidou-Solomidou, Melpo; Muzykantov, Vladimir R
Published In J Control Release, (2016 07 28)
Abstract: Controlled endothelial delivery of SOD may alleviate abnormal local surplus of superoxide involved in ischemia-reperfusion, inflammation and other disease conditions. Targeting SOD to endothelial surface vs. intracellular compartments is desirable to prevent pathological effects of external vs. endogenous superoxide, respectively. Thus, SOD conjugated with antibodies to cell adhesion molecule PECAM (Ab/SOD) inhibits pro-inflammatory signaling mediated by endogenous superoxide produced in the endothelial endosomes in response to cytokines. Here we defined control of surface vs. endosomal delivery and effect of Ab/SOD, focusing on conjugate size and targeting to PECAM vs. ICAM. Ab/SOD enlargement from about 100 to 300nm enhanced amount of cell-bound SOD and protection against extracellular superoxide. In contrast, enlargement inhibited endocytosis of Ab/SOD and diminished mitigation of inflammatory signaling of endothelial superoxide. In addition to size, shape is important: endocytosis of antibody-coated spheres was more effective than that of polymorphous antibody conjugates. Further, targeting to ICAM provides higher endocytic efficacy than targeting to PECAM. ICAM-targeted Ab/SOD more effectively mitigated inflammatory signaling by intracellular superoxide in vitro and in animal models, although total uptake was inferior to that of PECAM-targeted Ab/SOD. Therefore, both geometry and targeting features of Ab/SOD conjugates control delivery to cell surface vs. endosomes for optimal protection against extracellular vs. endosomal oxidative stress, respectively.
PubMed ID: 27210108
MeSH Terms: Animals; Antibodies, Monoclonal/administration & dosage*; Antibodies, Monoclonal/pharmacokinetics; Antibodies, Monoclonal/pharmacology; Drug Delivery Systems/methods*; Endocytosis/drug effects; Endosomes/metabolism; Endothelium, Vascular/drug effects*; Endothelium, Vascular/metabolism; Endotoxemia/drug therapy; Human Umbilical Vein Endothelial Cells; Immunoconjugates/administration & dosage*; Immunoconjugates/pharmacokinetics; Immunoconjugates/pharmacology; Intercellular Adhesion Molecule-1/immunology*; Mice, Inbred C57BL; Nanoparticles/chemistry; Oxidative Stress/drug effects; Platelet Endothelial Cell Adhesion Molecule-1/immunology*; Superoxide Dismutase/administration & dosage*; Superoxide Dismutase/pharmacokinetics; Superoxide Dismutase/pharmacology; Superoxides/metabolism